ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ZM001

A development code. Also written as “ZM001 Injection”.

Its studies are mostly in Lupus Erythematosus, Systemic, led by Imunopharm Technology.

Furthest: phase 1, since Feb 18, 20251 company-led study, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Imunopharm Technology11 open or runningphase 1since Feb 18, 2025Feb 18, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 18, 2025First study: phase 1 study in Lupus Erythematosus, SystemicFirst studyNCT06852573 · 18 planned

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06852573Lupus Erythematosus, Systemic1Not yet recruitingFeb 20, 202618

How it is read

Names in the registry

  • “ZM001 Injection”, 1 entry

Codes read as this program: ZM001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.